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Synchronous esophageal and gastric cancers with the patho-
logic features of a squamous cell carcinoma are extremely 
rare. A 57-year-old male visited our hospital with a history of he-
matemesis and was diagnosed with a synchronous cancer. He 
underwent a staging work-up, and the resectable lesion in the 
stomach was operated on following radiologic and endoscopic 
evaluations. The pathologic examination revealed a synchro-
nous cancer consisting of squamous cell carcinoma in the distal 
esophagus and the cardia of the stomach. We report a case of 
a synchronous cancer that was successfully treated by surgical 
resection followed by concurrent chemoradiotherapy. We also 
discuss the hypothesis regarding the origin and presentation of 
the synchronous cancer and highlight the importance of careful 
surveillance by physicians at the time of diagnosis. (Gut Liver 
2012;6:118-121)
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INTRODUCTION
A synchronous cancer of squamous cell origin found in the 
esophagus and stomach is very rare among gastrointestinal can-
cers. Squamous cell carcinomas take up 38% of all esophageal 
cancers, and it is common in esophagus, but not in stomach.1,2 
Less than 100 cases were reported until now.3 A synchronous 
presentation of squamous cell carcinoma in the esophagus and 
stomach is so rare that it has not been reported in Korea, yet. 
Therefore, making an accurate diagnosis is crucial in order to 
plan treatment for the synchronous cancer. We have experi-
enced a squamous cell carcinoma of esophagus and stomach 
and therein report this case to demonstrate that the cancer can 
be treated through accurate diagnosis, effective surgery and 
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combination of chemoradiation therapy.
CASE REPORT
A 57 year old male was admitted to the Department of Oncol-
ogy complaining of dyspepsia for 2 months and sudden onset 
of hematemesis. He underwent endoscopy and computed to-
mography (CT) and was diagnosed with esophageal cancer and 
stomach cancer. He had a history of complete atrioventricular 
block and had a pacemaker implemented in 1992. He had dia-
betes mellitus and his social history was significant for drinking 
a bottle of alcohol daily and smoking one pack of cigarettes for 
30 years. He had no significant family history. 
He was chronic ill-looking, and alert. His blood pressure was 
120/80 mm Hg, pulse 60/min, respiration 20/min, body tem-
perature 36.5oC. His skin was dry and warm, with pale icterus 
and dry tongue. His lungs were clear to auscultation and his 
heart was regular without murmur or rubs. His bowel move-
ment was normal without abdominal pain or tenderness. His 
liver and spleen were not palpable. The complete blood count 
showed white blood cell count 9,610/mm3, Hb 10.4 g/dL, Plt 
284×103/mm3. His blood chemistry was normal, with tumor 
markers carcinoembryonic antigen (CEA) 2.22 ng/mL and squa-
mous cell carcinoma antigen (SCC Ag) 2.2 μg/L. The chest X-
ray and simple abdomen showed no abnormality. On CT, there 
was an ulcerofungating mass from the pylorus of the stomach 
to lower esophagus. The stomach lesion was abutting the tail 
of the pancreas and the diaphragm on CT (Fig. 1). The positron 
emission tomography-computed tomography (PET-CT) showed 
no distant metastasis other than suspicious cancerous lesion in 
stomach and esophagus. He then underwent upper gastrointes-
tinal endoscopy and endoscopic ultrasound with biopsy. The 
endoscopic finding revealed an irregular shaped lesion with 
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decreased vascular marking from 31 to 39 cm from upper inci-
sor. The main cancer lesion in the esophagus was 35 cm from 
UI with serosa invasion and local lymph node metastasis. It 
was poorly-differentiated squamous cell carcinoma (Fig. 2). The 
stomach lesion was Bormann III shaped, moderately-differenti-
ated squamous cell carcinoma, with serosa exposure and local 
lymph node invasion by 9 mm (Fig. 3).
According to above findings, the stomach lesion was resect-
able and he underwent total gastrectomy and esophagoduo-
denostomy.4 The operative findings showed a 6×6 cm sized-
ulcerofungating mass in the lesser curvature of the stomach that 
invaded soft tissue of the pancreas (Fig. 4). There was no distant 
metastasis to liver or rectum. Postoperative findings demon-
strated a squamous cell carcinoma of the stomach, pT4N2M0 
with serosa invasion, 4 out of 41 local lymph nodes metastasis 
with perineurovascular invasion. The pathologic finding showed 
that the proximal resection margin of the gastric lesion was 
negative. This suggests the squamous cell carcinoma of the 
stomach was not a direct extension from squamous cell car-
cinoma of esophagus. They were indeed two separate cancers 
with different pathology. 
The patient was in good condition after the surgery, and 
underwent combination chemoradiotherapy (5-Fluorouracil/
Cisplatin: 5FU 1 g/m2 per day on the first 4 days of weeks 1, 5, 
8, and 11th weeks, Cisplatin 75 mg/m2 on first days of 1, 5, 8, 
11th weeks, Radiotherapy 2.0 Gy for 5 days a week). He is now 
in complete remission and regularly followed up in outpatient 
clinic.
DISCUSSION
There have been a few reports on the double primary cancers 
consisting of esophageal squamous cell carcinomas and gastric 
adenocarcinomas, but squamous cell carcinoma of stomach is a 
rare finding as described in this report. Recently, there has been 
increasing incidence of esophageal cancers associated with Bar-
Fig. 1. (A) An abdominopelvic com-
puted tomography shows an ulcero-
fungating mass at the gastric fundus 
(B) that extended to the esophago-
gastric junction and distal esophagus 
with serosal exposure.
Fig. 2. (A) Microscopic findings of invasive squamous cell carcinoma obtained from the esophagus (H&E stain, ×40). (B) The lesion is poorly dif-
ferentiated (H&E stain, ×200).
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rett’s esophagus. Adenocarcinomas increased by six-fold from 
1975 to 2001, while 97 percent of adenocarcinoma arising from 
esophagogastric junction is associated with Barrett’s esopha-
gus.5,6 The prevalence of squamous cell carcinoma is on the de-
cline, but still common in Asia in association with smoking and 
alcohol consumption.7,8 
The metastasis of esophageal cancer occurs commonly 
through lymphatic systems, and intramural metastasis plays an 
important role in tumor distribution. Intramural metastasis is 
known to have a poor prognosis. Among 1,259 patients who 
received surgical resection of esophageal cancers, 93 (7.4%) 
had intramural metastasis, and 13 (1.0%) had gastric metastasis 
among them. These metastatic lesions looked similar to gastric 
submucosal tumor, which suggested that metastasis occurred 
through lymphatic systems.9
To diagnosis a synchronous cancer, three conditions should 
be satisfied. First of all, cancer lesions should be located apart 
from each other, and should not be contiguous. Secondly, they 
must be pathologically different. Thirdly, both lesions should 
have mucosal lesions. In our case, the postoperative patho-
logic findings showed that the proximal resection margin of 
the gastric lesion was negative, which implies that two lesions 
were located separately. That is, the cancer originates from two 
lesions; one from the lower esophagus and the other from the 
gastric fundus. Moreover, the fact that the level of differentia-
tion was different in two lesions suggests that they arise from 
different origins. Valduga et al.10 reported a synchronous cancer 
with undifferentiated squamous cell carcinoma of stomach and 
well-differentiated squamous cell carcinoma of esophagus. In 
this regard, the main lesion of the synchronous cancer occurred 
from the fundus of the stomach reaching the esophagogastric 
junction, and the lower esophagus. 
Squamous cell carcinoma mainly occurs in the mid to lower 
esophagus, and it is not uncommon to have other accompany-
ing cancerous lesions. Suzuki et al.11 reported that the most 
common lesion is the stomach (59.6%), and then colon and rec-
tum (12.3%) in the order of frequency. Also, it has been reported 
that the mortality from the accompanying cancerous lesions is 
higher than the mortality from the esophageal cancer itself.12 
Therefore, it is important to consider the possibility of other 
existing cancers other than the esophagus. Since the only cura-
tive treatment of esophageal cancer or gastric fundus cancer is 
surgical resection, it is imperative that we examine the possible 
metastatic lesions thoroughly before deciding the operation.
Until now, the standard therapy of advanced esophageal can-
Fig. 3. (A) The cancer mucosa compared to the normal mucosa obtained from the lesser curvature of the upper body of the stomach (H&E stain, 
×40). (B) The invasive squamous cell carcinoma of the stomach is moderately differentiated (H&E stain, ×200).
Fig. 4. A gross specimen from the stomach after total gastrectomy, 
pT4N2M0. There is an ulcerofungating mass measuring 6×6 cm in 
the lesser curvature of the cardia. It is located 1.3 cm from the proxi-
mal resection margin and 12.5 cm from the distal resection margin. 
Both the proximal and distal resection margins are shown to be free 
of carcinoma (a safety margin of 1.3 cm and a safety margin of 12.5 
cm, respectively).
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cer is combined modality therapy: 50 Gy in 25 fractions over 5 
weeks, plus cisplatin intravenously on the first day of weeks 1, 5, 
8, and 11, and fluorouracil, 1 g/m2 per day by continuous infu-
sion on the first 4 days of weeks 1, 5, 8, and 11. In a random-
ized trial, combined therapy increased the survival of patients 
who have squamous cell or adenocarcinoma of the esophagus, 
compared with radiotherapy alone.13,14
In this case, we demonstrated the synchronous cancer of 
squamous cell origin in the esophagus and stomach. Esophageal 
cancer tends to spread axially, up and down the length of the 
organ and to regional lymphatics, producing morbidity and 
mortality. However, another cancer can be discovered synchro-
nously. Therefore, when making a diagnosis, staging a cancer 
and evaluating treatment response, we should be aware that 
there may be potential cancer lesions other than the esophagus. 
Through prudent diagnosis and treatment plan, complete resec-
tion of the tumor burden and chemoradiation therapy for the 
unresectable lesion will lead to improvement in patient survival.
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